{
    "id": 10202,
    "fullName": "NFE2L2 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NFE2L2 mutant indicates an unspecified mutation in the NFE2L2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4780,
        "geneSymbol": "NFE2L2",
        "terms": [
            "NFE2L2",
            "HEBP1",
            "IMDDHH",
            "Nrf-2",
            "NRF2"
        ]
    },
    "variant": "mutant",
    "createDate": "08/05/2015",
    "updateDate": "02/07/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17257,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Sapanisertib (MLN0128) treatment resulted in an objective response rate of 29% (2/7, 2 partial response) and a disease control rate of 100% (7/7) in lung squamous cell carcinoma patients harboring NFE2L2 mutations (J Clin Oncol 37, 2019 (suppl; abstr 9085)).",
            "molecularProfile": {
                "id": 10205,
                "profileName": "NFE2L2 mutant"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15277,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_265315.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16649,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, non-small cell lung cancer patients harboring KEAP1 or NFE2L2 mutations (n=9) demonstrated higher incidence of local recurrence at 30-months after radiotherapy (70% vs 18%, p<0.003) compared to KEAP1/NFE2L2 wild-type patients (n=33) (PMID: 27663899).",
            "molecularProfile": {
                "id": 10205,
                "profileName": "NFE2L2 mutant"
            },
            "therapy": {
                "id": 3841,
                "therapyName": "Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14009,
                    "pubMedId": 27663899,
                    "title": "Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27663899"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11545,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with MCL1 amplification and a NFE2L2 missense mutation, experienced disease progression after initial response to Zykadia (ceritinib) treatment for 7 months, then received Alecensa (alectinib) and remained on treatment for at least 45 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28132,
                "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11546,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with MCL1 amplification and a NFE2L2 missense mutation, experienced disease progression after initial response to Zykadia (ceritinib) treatment for 7 months, then received Alecensa (alectinib) and remained on treatment for at least 45 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28132,
                "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10205,
            "profileName": "NFE2L2 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28132,
            "profileName": "EML4 - ALK MCL1 amp NFE2L2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31317,
            "profileName": "KEAP1 mut NFE2L2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}